论文部分内容阅读
目的:探讨使用克唑替尼治疗EML4-ALK阳性的晚期非小细胞肺癌的临床疗效分析。方法:将我院肿瘤科2013年7月-2015t年7月期间收治的确诊为EML4-ALK阳性的晚期非小细胞肺癌患者30例,将患者分为治疗组和对照组各15例,其中对对照组的患者进行多西他赛单药化疗,而治疗组的患者使用口服克唑替尼治疗,以连续治疗21天为一个疗程,治疗三个疗程之后对比两组患者的临床资料,分析患者的临床治疗效果。结果:治疗组的患者当中有9例患者的肿瘤细胞得到了有效的控制,总的治疗有效率为60%,而对照组的患者当中的治疗有效率为40%,结果具有明显差异(P<0.05)。同时,治疗组患者有1例患者出现了明显的呕吐副作用,而对照组当中有6例患者发生不良反应。讨论:使用克唑替尼用于治疗EML4-ALK阳性的晚期非小细胞肺癌患者不仅较传统的治疗药物有更好的效果,而且药物不良反应更低,因此可以考虑将克唑替尼作为治疗EML4-ALK阳性的晚期非小细胞肺癌的一线治疗方案。
Objective: To investigate the clinical efficacy of crizotinib in the treatment of EML4-ALK positive advanced non-small cell lung cancer. Methods: Thirty patients with advanced non-small cell lung cancer diagnosed as EML4-ALK positive from July 2013 to July 2015 were enrolled in this study. The patients were divided into treatment group (n = 15) and control group (n = 15) Among them, patients in the control group were treated with docetaxel single-agent chemotherapy, while those in the treatment group were treated with oral crizotinib. One course of continuous treatment was 21 days. After three courses of treatment, the clinical data of two groups of patients were compared. Analysis of the patient’s clinical treatment. RESULTS: Tumor cells were effectively controlled in 9 of the patients in the treatment group, with an overall response rate of 60%, compared with 40% in the control group, with significant differences (P < 0.05). At the same time, one patient in the treatment group had significant vomiting side effects, while 6 patients in the control group developed adverse reactions. Discussion: The use of crizotinib for the treatment of EML4-ALK-positive patients with advanced non-small cell lung cancer is not only more effective than traditional therapies, but also with less adverse drug reactions, so crizotinib may be considered as a treatment First-line treatment of EML4-ALK-positive advanced non-small cell lung cancer.